CA2988579A1 - Compositions et procedes permettant d'augmenter la sensibilite des bacteries aux antibiotiques - Google Patents

Compositions et procedes permettant d'augmenter la sensibilite des bacteries aux antibiotiques Download PDF

Info

Publication number: CA2988579A1
Authority: CA; Canada
Prior art keywords: composition; agent; agglomeration; antibacterial agent; individual
Prior art date: 2015-04-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2988579A

Other languages

English (en)

Inventor

Ping-Chuan Christina Tsai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Epibiome Inc

Original Assignee

Epibiome Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-21

Filing date

2016-04-21

Publication date

2016-10-27

2016-04-21 Application filed by Epibiome Inc filed Critical Epibiome Inc

2016-10-27 Publication of CA2988579A1 publication Critical patent/CA2988579A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 494
239000003242 anti bacterial agent Substances 0.000 title claims abstract description 276
241000894006 Bacteria Species 0.000 title claims abstract description 196
238000000034 method Methods 0.000 title claims abstract description 178
229940088710 antibiotic agent Drugs 0.000 title description 17
238000005054 agglomeration Methods 0.000 claims abstract description 296
239000003795 chemical substances by application Substances 0.000 claims abstract description 262
230000002776 aggregation Effects 0.000 claims abstract description 67
235000013305 food Nutrition 0.000 claims abstract description 60
239000004365 Protease Substances 0.000 claims description 222
239000002671 adjuvant Substances 0.000 claims description 149
210000004027 cell Anatomy 0.000 claims description 114
241001515965 unidentified phage Species 0.000 claims description 105
108010004032 Bromelains Proteins 0.000 claims description 86
235000019835 bromelain Nutrition 0.000 claims description 86
230000003115 biocidal effect Effects 0.000 claims description 79
108091005804 Peptidases Proteins 0.000 claims description 75
235000019419 proteases Nutrition 0.000 claims description 70
150000003384 small molecules Chemical class 0.000 claims description 68
108090000526 Papain Proteins 0.000 claims description 65
235000019834 papain Nutrition 0.000 claims description 64
229940055729 papain Drugs 0.000 claims description 63
108090000623 proteins and genes Proteins 0.000 claims description 57
239000002738 chelating agent Substances 0.000 claims description 56
239000003638 chemical reducing agent Substances 0.000 claims description 56
102000004169 proteins and genes Human genes 0.000 claims description 55
-1 desfurolyceftiofur Chemical compound 0.000 claims description 51
108010062877 Bacteriocins Proteins 0.000 claims description 47
239000006041 probiotic Substances 0.000 claims description 47
235000018291 probiotics Nutrition 0.000 claims description 47
230000000529 probiotic effect Effects 0.000 claims description 46
208000035143 Bacterial infection Diseases 0.000 claims description 43
229960000723 ampicillin Drugs 0.000 claims description 42
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 42
208000022362 bacterial infectious disease Diseases 0.000 claims description 42
HBJOXQRURQPDEX-MHXMMLMNSA-N (2s,4r)-n-[(1s,2s)-2-chloro-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-ethylpiperidine-2-carboxamide Chemical compound C1[C@H](CC)CCN[C@@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 HBJOXQRURQPDEX-MHXMMLMNSA-N 0.000 claims description 41
210000001035 gastrointestinal tract Anatomy 0.000 claims description 35
UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 claims description 33
229960004350 cefapirin Drugs 0.000 claims description 33
241000191967 Staphylococcus aureus Species 0.000 claims description 31
229960001635 pirlimycin Drugs 0.000 claims description 31
102000004190 Enzymes Human genes 0.000 claims description 26
108090000790 Enzymes Proteins 0.000 claims description 26
229940088598 enzyme Drugs 0.000 claims description 26
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 24
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 23
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 23
238000011109 contamination Methods 0.000 claims description 22
235000013365 dairy product Nutrition 0.000 claims description 22
108060003951 Immunoglobulin Proteins 0.000 claims description 21
241000194042 Streptococcus dysgalactiae Species 0.000 claims description 21
101710120037 Toxin CcdB Proteins 0.000 claims description 21
102000018358 immunoglobulin Human genes 0.000 claims description 21
230000018612 quorum sensing Effects 0.000 claims description 21
241000193163 Clostridioides difficile Species 0.000 claims description 20
241000194054 Streptococcus uberis Species 0.000 claims description 20
229940012957 plasmin Drugs 0.000 claims description 20
229940115920 streptococcus dysgalactiae Drugs 0.000 claims description 20
229940115922 streptococcus uberis Drugs 0.000 claims description 20
230000001420 bacteriolytic effect Effects 0.000 claims description 18
230000036541 health Effects 0.000 claims description 18
208000004396 mastitis Diseases 0.000 claims description 15
210000001519 tissue Anatomy 0.000 claims description 15
WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 14
241000193830 Bacillus <bacterium> Species 0.000 claims description 14
241000193468 Clostridium perfringens Species 0.000 claims description 14
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 14
102000008946 Fibrinogen Human genes 0.000 claims description 14
108010049003 Fibrinogen Proteins 0.000 claims description 14
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 14
229960002626 clarithromycin Drugs 0.000 claims description 14
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 14
229940047766 co-trimoxazole Drugs 0.000 claims description 14
229940012952 fibrinogen Drugs 0.000 claims description 14
210000004369 blood Anatomy 0.000 claims description 13
239000008280 blood Substances 0.000 claims description 13
108090000712 Cathepsin B Proteins 0.000 claims description 12
102000004225 Cathepsin B Human genes 0.000 claims description 12
108090000270 Ficain Proteins 0.000 claims description 12
101700012268 Holin Proteins 0.000 claims description 12
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
101710126949 Lysin Proteins 0.000 claims description 12
101710166729 Tail fiber protein Proteins 0.000 claims description 12
108010014251 Muramidase Proteins 0.000 claims description 11
108090000284 Pepsin A Proteins 0.000 claims description 11
102000057297 Pepsin A Human genes 0.000 claims description 11
108090000350 actinidain Proteins 0.000 claims description 11
210000000988 bone and bone Anatomy 0.000 claims description 11
235000019836 ficin Nutrition 0.000 claims description 11
239000004325 lysozyme Substances 0.000 claims description 11
229960000274 lysozyme Drugs 0.000 claims description 11
235000010335 lysozyme Nutrition 0.000 claims description 11
210000005075 mammary gland Anatomy 0.000 claims description 11
ZHQQRIUYLMXDPP-SSDOTTSWSA-N Actinidine Natural products C1=NC=C(C)C2=C1[C@H](C)CC2 ZHQQRIUYLMXDPP-SSDOTTSWSA-N 0.000 claims description 10
210000003709 heart valve Anatomy 0.000 claims description 10
210000004072 lung Anatomy 0.000 claims description 10
210000001331 nose Anatomy 0.000 claims description 10
229940111202 pepsin Drugs 0.000 claims description 10
210000003800 pharynx Anatomy 0.000 claims description 10
241000186660 Lactobacillus Species 0.000 claims description 9
229940039696 lactobacillus Drugs 0.000 claims description 9
210000003491 skin Anatomy 0.000 claims description 9
QJVHTELASVOWBE-AGNWQMPPSA-N (2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 QJVHTELASVOWBE-AGNWQMPPSA-N 0.000 claims description 7
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 7
241000186000 Bifidobacterium Species 0.000 claims description 7
ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 claims description 7
UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 7
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 7
229930182566 Gentamicin Natural products 0.000 claims description 7
GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 7
229930193140 Neomycin Natural products 0.000 claims description 7
239000004100 Oxytetracycline Substances 0.000 claims description 7
229930182555 Penicillin Natural products 0.000 claims description 7
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
229930195708 Penicillin V Natural products 0.000 claims description 7
239000004098 Tetracycline Substances 0.000 claims description 7
HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 7
239000004182 Tylosin Substances 0.000 claims description 7
229930194936 Tylosin Natural products 0.000 claims description 7
108010059993 Vancomycin Proteins 0.000 claims description 7
229960004821 amikacin Drugs 0.000 claims description 7
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 7
229960003022 amoxicillin Drugs 0.000 claims description 7
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 7
229960004099 azithromycin Drugs 0.000 claims description 7
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 7
229960005361 cefaclor Drugs 0.000 claims description 7
QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 7
229960004841 cefadroxil Drugs 0.000 claims description 7
NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 7
229960005229 ceftiofur Drugs 0.000 claims description 7
ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 claims description 7
229940106164 cephalexin Drugs 0.000 claims description 7
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 7
229960003405 ciprofloxacin Drugs 0.000 claims description 7
229960002227 clindamycin Drugs 0.000 claims description 7
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 7
229960001585 dicloxacillin Drugs 0.000 claims description 7
YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 7
229960002222 dihydrostreptomycin Drugs 0.000 claims description 7
ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 claims description 7
229960003722 doxycycline Drugs 0.000 claims description 7
229960003276 erythromycin Drugs 0.000 claims description 7
229960004273 floxacillin Drugs 0.000 claims description 7
NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims description 7
229960000588 flunixin Drugs 0.000 claims description 7
229960002518 gentamicin Drugs 0.000 claims description 7
229960003376 levofloxacin Drugs 0.000 claims description 7
229960004196 lymecycline Drugs 0.000 claims description 7
AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 claims description 7
229960000282 metronidazole Drugs 0.000 claims description 7
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 7
229960000515 nafcillin Drugs 0.000 claims description 7
GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 7
229960004927 neomycin Drugs 0.000 claims description 7
229960001180 norfloxacin Drugs 0.000 claims description 7
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 7
229960001019 oxacillin Drugs 0.000 claims description 7
UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 7
229960000625 oxytetracycline Drugs 0.000 claims description 7
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 7
235000019366 oxytetracycline Nutrition 0.000 claims description 7
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 7
229940049954 penicillin Drugs 0.000 claims description 7
229940056367 penicillin v Drugs 0.000 claims description 7
BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 7
229960004306 sulfadiazine Drugs 0.000 claims description 7
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 7
ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 claims description 7
229960000973 sulfadimethoxine Drugs 0.000 claims description 7
229960002135 sulfadimidine Drugs 0.000 claims description 7
ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 claims description 7
229960005404 sulfamethoxazole Drugs 0.000 claims description 7
JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 7
229960001544 sulfathiazole Drugs 0.000 claims description 7
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims description 7
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 7
229960002180 tetracycline Drugs 0.000 claims description 7
229930101283 tetracycline Natural products 0.000 claims description 7
235000019364 tetracycline Nutrition 0.000 claims description 7
150000003522 tetracyclines Chemical class 0.000 claims description 7
229960000223 tilmicosin Drugs 0.000 claims description 7
JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 claims description 7
229960005053 tinidazole Drugs 0.000 claims description 7
229960000707 tobramycin Drugs 0.000 claims description 7
229960004059 tylosin Drugs 0.000 claims description 7
WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims description 7
235000019375 tylosin Nutrition 0.000 claims description 7
229960003165 vancomycin Drugs 0.000 claims description 7
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 7
238000001802 infusion Methods 0.000 claims description 6
210000002966 serum Anatomy 0.000 claims description 5
210000003722 extracellular fluid Anatomy 0.000 claims description 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
102000016943 Muramidase Human genes 0.000 claims 2
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 2
239000003814 drug Substances 0.000 abstract description 10
238000001727 in vivo Methods 0.000 abstract description 8
238000000338 in vitro Methods 0.000 abstract description 7
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 96
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 95
235000018417 cysteine Nutrition 0.000 description 95
102000035195 Peptidases Human genes 0.000 description 69
230000001580 bacterial effect Effects 0.000 description 65
235000020185 raw untreated milk Nutrition 0.000 description 61
235000013336 milk Nutrition 0.000 description 60
210000004080 milk Anatomy 0.000 description 60
239000008267 milk Substances 0.000 description 60
229940027941 immunoglobulin g Drugs 0.000 description 59
230000004520 agglutination Effects 0.000 description 52
235000018102 proteins Nutrition 0.000 description 51
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 38
241000283690 Bos taurus Species 0.000 description 37
241001468181 Streptococcus sp. 'group C' Species 0.000 description 25
241000194005 Streptococcus sp. 'group G' Species 0.000 description 25
241001465754 Metazoa Species 0.000 description 21
241000239110 Staphylococcus virus K Species 0.000 description 21
239000001974 tryptic soy broth Substances 0.000 description 21
108010050327 trypticase-soy broth Proteins 0.000 description 21
201000010099 disease Diseases 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
230000002401 inhibitory effect Effects 0.000 description 19
230000000694 effects Effects 0.000 description 17
239000008194 pharmaceutical composition Substances 0.000 description 16
230000005764 inhibitory process Effects 0.000 description 15
230000002147 killing effect Effects 0.000 description 15
239000003899 bactericide agent Substances 0.000 description 14
238000011534 incubation Methods 0.000 description 14
208000015181 infectious disease Diseases 0.000 description 14
108010025955 Pyocins Proteins 0.000 description 13
230000000844 anti-bacterial effect Effects 0.000 description 13
238000002203 pretreatment Methods 0.000 description 12
208000031462 Bovine Mastitis Diseases 0.000 description 10
102000005927 Cysteine Proteases Human genes 0.000 description 10
108010005843 Cysteine Proteases Proteins 0.000 description 10
241000196324 Embryophyta Species 0.000 description 10
108010053775 Nisin Proteins 0.000 description 10
NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 10
239000004309 nisin Substances 0.000 description 10
235000010297 nisin Nutrition 0.000 description 10
229940101096 pirsue Drugs 0.000 description 10
102100033468 Lysozyme C Human genes 0.000 description 9
238000003556 assay Methods 0.000 description 9
238000004132 cross linking Methods 0.000 description 9
208000024891 symptom Diseases 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
244000052616 bacterial pathogen Species 0.000 description 8
230000001332 colony forming effect Effects 0.000 description 8
241000700159 Rattus Species 0.000 description 7
241000194017 Streptococcus Species 0.000 description 7
241000607479 Yersinia pestis Species 0.000 description 7
238000009472 formulation Methods 0.000 description 7
244000052769 pathogen Species 0.000 description 7
238000013207 serial dilution Methods 0.000 description 7
241000238631 Hexapoda Species 0.000 description 6
239000003995 emulsifying agent Substances 0.000 description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000000126 substance Substances 0.000 description 6
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000000758 substrate Substances 0.000 description 5
NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 5
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 5
208000037384 Clostridium Infections Diseases 0.000 description 4
206010009657 Clostridium difficile colitis Diseases 0.000 description 4
206010054236 Clostridium difficile infection Diseases 0.000 description 4
201000003883 Cystic fibrosis Diseases 0.000 description 4
108010088842 Fibrinolysin Proteins 0.000 description 4
108010046377 Whey Proteins Proteins 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
231100000075 skin burn Toxicity 0.000 description 4
241000894007 species Species 0.000 description 4
238000005507 spraying Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
101710198480 Clumping factor A Proteins 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010024636 Glutathione Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010072170 Skin wound Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
230000002550 fecal effect Effects 0.000 description 3
229960003180 glutathione Drugs 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
230000007688 immunotoxicity Effects 0.000 description 3
231100000386 immunotoxicity Toxicity 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000013372 meat Nutrition 0.000 description 3
229960003151 mercaptamine Drugs 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
244000045947 parasite Species 0.000 description 3
238000007747 plating Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
235000020991 processed meat Nutrition 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
235000021119 whey protein Nutrition 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000031729 Bacteremia Diseases 0.000 description 2
240000006432 Carica papaya Species 0.000 description 2
235000009467 Carica papaya Nutrition 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
102000005593 Endopeptidases Human genes 0.000 description 2
108010059378 Endopeptidases Proteins 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
241000187479 Mycobacterium tuberculosis Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010031252 Osteomyelitis Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
239000000022 bacteriostatic agent Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
229940009063 cephapirin sodium Drugs 0.000 description 2
VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 description 2
230000008859 change Effects 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000645 desinfectant Substances 0.000 description 2
230000001066 destructive effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
206010014665 endocarditis Diseases 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
230000016178 immune complex formation Effects 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
210000002429 large intestine Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000009877 rendering Methods 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
239000006150 trypticase soy agar Substances 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
108091005508 Acid proteases Proteins 0.000 description 1
235000009434 Actinidia chinensis Nutrition 0.000 description 1
244000298697 Actinidia deliciosa Species 0.000 description 1
235000009436 Actinidia deliciosa Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
229920002799 BoPET Polymers 0.000 description 1
208000004020 Brain Abscess Diseases 0.000 description 1
241000234670 Bromeliaceae Species 0.000 description 1
101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 1
101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
101000986479 Carica papaya Papain Proteins 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010073254 Colicins Proteins 0.000 description 1
101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 1
102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016936 Folliculitis Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010021531 Impetigo Diseases 0.000 description 1
241000256602 Isoptera Species 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000005041 Mylar™ Substances 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
208000032536 Pseudomonas Infections Diseases 0.000 description 1
101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 1
101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 1
101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 1
101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 1
101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
102000035100 Threonine proteases Human genes 0.000 description 1
108091005501 Threonine proteases Proteins 0.000 description 1
206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000037815 bloodstream infection Diseases 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229960002433 cysteine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
201000010582 ecthyma Diseases 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000009459 flexible packaging Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
108090000285 fruit bromelain Proteins 0.000 description 1
230000006870 function Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000004293 human mammary gland Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000011368 organic material Substances 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000020200 pasteurised milk Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
238000001066 phage therapy Methods 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
230000008261 resistance mechanism Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
108090000346 stem bromelain Proteins 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003611 tocopherol derivatives Chemical class 0.000 description 1
239000008181 tonicity modifier Substances 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
235000021241 α-lactalbumin Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22002—Papain (3.4.22.2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22004—Bromelain (3.4.22.4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Mycology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2988579A 2015-04-21 2016-04-21 Compositions et procedes permettant d'augmenter la sensibilite des bacteries aux antibiotiques Abandoned CA2988579A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562150294P	2015-04-21	2015-04-21
US62/150,294		2015-04-21
US201562249115P	2015-10-30	2015-10-30
US62/249,115		2015-10-30
PCT/US2016/028703 WO2016172380A1 (fr)	2015-04-21	2016-04-21	Compositions et procédés permettant d'augmenter la sensibilité des bactéries aux antibiotiques

Publications (1)

Publication Number	Publication Date
CA2988579A1 true CA2988579A1 (fr)	2016-10-27

Family

ID=57144243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2988579A Abandoned CA2988579A1 (fr)	2015-04-21	2016-04-21	Compositions et procedes permettant d'augmenter la sensibilite des bacteries aux antibiotiques

Country Status (4)

Country	Link
EP (1)	EP3285587A1 (fr)
AU (1)	AU2016250606A1 (fr)
CA (1)	CA2988579A1 (fr)
WO (1)	WO2016172380A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11311582B2 (en)	2015-11-19	2022-04-26	Locus Biosciences, Inc.	Bacteriophage compositions and methods of use thereof
US11015154B2 (en)	2016-11-09	2021-05-25	The Regents Of The University Of California	Methods for identifying interactions amongst microorganisms
WO2018106945A1 (fr)	2016-12-07	2018-06-14	Progenity Inc.	Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
CN106620668A (zh) *	2017-01-02	2017-05-10	武汉新联大生物有限公司	一种复方替米考星固体分散剂及其制备方法
WO2018183941A2 (fr)	2017-03-30	2018-10-04	Progenity Inc.	Traitement d'une maladie du tractus gastro-intestinal avec un agent biothérapeutique vivant
US20190298835A1 (en) *	2018-03-29	2019-10-03	U.S. Army Research Laboratory	Administration of tailored feedstock to increase antibiotic susceptibility
IL260690A (en) *	2018-07-19	2018-12-31	Yeda Res & Dev	Sphingosine derivatives and their use against pulmonary bacterial infections
US11684597B2 (en) *	2019-01-28	2023-06-27	The United States Of America As Represented By The Secretary Of The Army	Administration of tailored feedstock to increase nitro-containing amphenicol antibiotic susceptibility
FR3110599B1 (fr) *	2020-05-19	2024-07-26	Vetophage	Nouvelles souches de bacteriophages et leurs utilisations
EP3972620A1 (fr) *	2019-05-21	2022-03-30	Vetophage	Nouvelles souches de bactériophages et leurs utilisations
FR3096374B1 (fr) *	2019-05-21	2024-10-25	Vetophage	Nouvelles souches de bacteriophages et leurs utilisations
CN110223734A (zh) *	2019-07-22	2019-09-10	华中农业大学	一种抗菌药物头孢噻呋药动-药效同步模型的构建方法及其应用
CN115666704B (zh)	2019-12-13	2025-09-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
CN113881607A (zh) *	2021-11-17	2022-01-04	宜兴市天石饲料有限公司	一种防治禽产气荚膜梭菌的研发方法
CN121694399A (zh) *	2026-02-12	2026-03-20	通威农业发展有限公司	一种具有抗菌消毒功能的草鱼饲料及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5252343A (en) *	1992-03-20	1993-10-12	Alcide Corporation	Method and composition for prevention and treatment of bacterial infections
CA3004707C (fr) *	2009-09-02	2022-05-31	Synedgen Inc.	Procedes et compositions pour detruire un biofilm au moyen de composes derives de chitosane
US20110053832A1 (en) *	2009-09-03	2011-03-03	Kraft Foods Global Brands Llc	Natural antimicrobial composition
WO2011063394A2 (fr) *	2009-11-23	2011-05-26	Olmstead Stephen F	Compositions et méthodes comprenant une peptidase serratia destinées à l'inhibition et au traitement de biofilms liés à certaines pathologies
GB2477914B (en) *	2010-02-12	2012-01-04	Univ Newcastle	Compounds and methods for biofilm disruption and prevention
EP2922555A4 (fr) *	2012-11-26	2016-06-15	Borody Thomas J	Compositions pour la restauration d'un microbiote fécal et leurs procédés de fabrication et d'utilisation

2016
- 2016-04-21 CA CA2988579A patent/CA2988579A1/fr not_active Abandoned
- 2016-04-21 EP EP16783881.2A patent/EP3285587A1/fr not_active Withdrawn
- 2016-04-21 AU AU2016250606A patent/AU2016250606A1/en not_active Abandoned
- 2016-04-21 WO PCT/US2016/028703 patent/WO2016172380A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2016172380A1 (fr)	2016-10-27
EP3285587A1 (fr)	2018-02-28
AU2016250606A1 (en)	2017-12-07

Legal Events

Date	Code	Title	Description
2020-11-07	FZDE	Dead	Effective date: 20200831

Publication	Publication Date	Title
CA2988579A1 (fr)	2016-10-27	Compositions et procedes permettant d'augmenter la sensibilite des bacteries aux antibiotiques
US12144845B2 (en)	2024-11-19	Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
Song et al.	2024	Staphylococcus aureus and biofilms: transmission, threats, and promising strategies in animal husbandry
Schmelcher et al.	2015	Synergistic streptococcal phage λSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis
Golban et al.	2025	Phage-derived endolysins against resistant Staphylococcus spp.: a review of features, antibacterial activities, and recent applications
Villageliu et al.	2022	The role of bacterial membrane vesicles in human health and disease
Wittekind et al.	2016	Cell wall hydrolases and antibiotics: exploiting synergy to create efficacious new antimicrobial treatments
Pieterse et al.	2010	Bacteriocins: exploring alternatives to antibiotics in mastitis treatment
US11311582B2 (en)	2022-04-26	Bacteriophage compositions and methods of use thereof
Simoes et al.	2017	Novel antibacterial agents: an emergent need to win the battle against infections
US20080207491A1 (en)	2008-08-28	Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections
George et al.	2012	Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128
Zaslavskaya et al.	2019	Prospects for using bacteriocins of normal microbiota in antibacterial therapy
Nisar et al.	2024	The clinical praxis of bacteriocins as natural anti-microbial therapeutics
US20240409910A1 (en)	2024-12-12	Recombinant polypeptide for use as a medicine, antiseptic agent, antibacterial agent, anti-inflammatory agent, compositions comprising it and uses thereof
CN110124012B (zh)	2023-06-16	一种颗粒溶素作为多粘菌素类抗生素增效剂的应用
Safarpour-Dehkordi et al.	2024	A comprehensive investigation of the medicinal efficacy of antimicrobial fusion peptides expressed in probiotic bacteria for the treatment of pan drug-resistant (PDR) infections
Zhang et al.	2016	A complex of trypsin and chymotrypsin effectively inhibited growth of pathogenic bacteria inducing cow mastitis and showed synergistic antibacterial activity with antibiotics
Basdew et al.	2011	Mini-Review: Biological control of bovine mastitis using bacteriophage therapy
Premlatha	2019	Microbial resistance to antibiotics
Veiga-Crespo et al.	2007	What can bacteriophages do for us
Zubareva et al.	2024	Alternative treatment methods for bovine mastitis: prospects and limitations
Oliveira et al.	2019	Bacteriophage proteins as antimicrobials to combat antibiotic resistance
US20220193186A1 (en)	2022-06-23	Method of treating and preventing bone and joint infections
Gadelii et al.	2019	Sensitizing agents to restore antibiotic resistance